Zack’s Investment Research Initiates Coverage of VeriTeQ Corporation with an Outperform Rating
February 12 2014 - 11:33AM
Business Wire
VeriTeQ Corporation (“VeriTeQ” or “Company”) (OTC Markets:VTEQ),
a provider of implantable medical device identification and
radiation dose measurement technologies, announced today that Zacks
Investment Research (“Zacks”) has initiated coverage of the Company
with an outperform rating.
Copies of the report may be obtained through Zacks Small Cap
website at http://scr.zacks.com or at
http://scr.zacks.com/files/doc_coverage/Med-Tech%20-%20Brian%20Marckx/VTEQ/February%2012%202014_VTEQ_Marckx.pdf.
Any opinions, judgments, estimates, or forecasts regarding the
Company's historical or predicted performance or operations made by
Zacks are its alone and do not represent opinions, judgments,
estimates, or forecasts of the Company or its management. The
Company does not by its reference to the research prepared by Zacks
imply its endorsement or adoption of or concurrence with such
information, conclusions, or recommendations.
About VeriTeQ
VeriTeQ is focused on the unique device identification (“UDI”)
of implantable and reusable medical devices through its Q Inside
Safety Technology, and radiation dose measurement during radiation
therapy. VeriTeQ’s FDA cleared Q Inside Safety Technology acts as
an electronic serial number in breast implants and other
implantable and reusable medical devices that gives physicians and
patients access to secure online databases to retrieve
device-specific data such as serial number, manufacturer name, date
of manufacture, lot number, volume, size, and other data from the
medical device manufacturer. Q Inside Safety Technology also
provides an extra level of protection to the patient in the event
of a recall or other safety event.
VeriTeQ’s radiation dosimeter, or biodosimetry, technologies
include the DVS SmartMarker® and OneDose®. DVS SmartMarker is the
world’s first FDA cleared, implantable, wireless radiation sensor,
and is used to measure the radiation dose delivered to a patient
directly from the site of the tumor during cancer treatment. DVS
SmartMarker is cleared for use in breast and prostate cancer
patients. Its OneDose® adhesive technology is FDA cleared for use
in cancer patients being treated with external beam radiation to
measure radiation dose levels at the skin surface.
VeriTeQ’s intellectual property portfolio includes more than 100
patents issued, patents pending, and patent licenses. VeriTeQ also
has data analytics capabilities related to information gathered by
its technologies.
For more information on VeriTeQ, please visit
www.veriteqcorp.com.
Statements in this press release about our future constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Litigation
Reform Act of 1995. Such forward-looking statements involve risks
and uncertainties and are subject to change at any time, and our
actual results could differ materially from expected results. These
risks and uncertainties include, without limitation, VeriTeQ’s
ability to commercially launch its Q Inside Safety Technology; the
Company’s ability to target the UDI sector and medical device
manufacturers; the Company’s ability to commercialize its radiation
dosimetry technologies; VeriTeQ’s ability to raise capital; as well
as other risks. Additional information about these and other
factors may be described in VeriTeQ’s Forms 10-Q, filed on August
9, 2013 and November 14, 2013, and future filings with the
Securities and Exchange Commission The Company undertakes no
obligation to update or release any revisions to these
forward-looking statements to reflect events or circumstances after
the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law.
VeriTeQAllison Tomek,
561-846-7003atomek@veriteqcorp.comorRedChip CompaniesBrendan
Hopkins, 1-800-RED-CHIP (733-2447) Ext 134Bhopkins@redchip.com
VeriTeQ (CE) (USOTC:VTEQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
VeriTeQ (CE) (USOTC:VTEQ)
Historical Stock Chart
From Apr 2023 to Apr 2024